BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells

Phase I CARLYSLE study: CAR T-cell therapy obe-cel shows favorable safety and clinical benefit in severe refractory lupus

This article reports initial results from the phase I CARLYSLE study evaluating obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-ce

China approves world's first CAR-T cell therapy for solid tumors: CARsgen's satri-cel for advanced gastric cancer

CARsgen Therapeutics has received approval from China's NMPA for satricabtagene autoleucel (satri-cel; CT041), the world's first CAR-T cell

Donor-derived stem cell memory CAR T cells show enhanced expansion and safety in post-HSCT relapse treatment

This first-in-human study (NCT01087294) investigates donor-derived CD19-CAR T cells for treating B cell malignancies relapsing after allogen

AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers

Researchers developed an AI-driven framework for discovering CAR T cell therapy targets by integrating single-cell RNA sequencing data from

Resetting autoimmune disease with CAR cell therapies